Hope Therapeutics, a subsidiary of NRx Pharmaceuticals (NASDAQ: NRXP), announced a partnership with Emobot Health to integrate AI-powered depression monitoring technology across its interventional psychiatry clinic network.

The partnership will deploy Emobot's "Depression Thermometer," which monitors depression, bipolar disorder and anxiety through smartphone analysis of facial expressions, vocal tones and activity patterns. The technology operates passively in the background without requiring patient questionnaires.

According to the company, approximately 50% of patients with treatment-resistant depression relapse within 6-12 months, often undetected between clinic visits. The AI monitoring aims to identify early relapse signals to enable timely interventions such as maintenance ketamine or transcranial magnetic stimulation sessions.

Clinical validation across three studies showed concordance with established depression rating scales, with correlation coefficients of 0.89 with the MADRS scale and 0.83 with PHQ-9 scores, according to the press release.

"Precision medicine requires real-time data to be effective," said Jonathan Javitt, founder and CEO of Hope Therapeutics. "In psychiatry, the period between clinic visits has traditionally been a 'blind spot.' Emobot's 100% passive, multimodal AI provides us with a continuous stream of objective biomarkers."

The Emobot app will provide patients with real-time mood and activity insights, with automatic notifications and in-app appointment scheduling if relapse risk is detected. Hope Therapeutics expects to have every patient use the platform.

Paris-based Emobot Health operates from the Paris Brain Institute and has partnerships with academic institutions including UC San Diego, Yale University and Johns Hopkins. Hope Therapeutics operates interventional psychiatry clinics specializing in treatment-resistant depression, PTSD and related conditions.